Drug trial aims to stop dangerous bleeding in patients with dual infections
NCT ID NCT03664518
Summary
This study tested whether the drug eltrombopag could safely raise platelet counts in adults who have both immune thrombocytopenia (a bleeding disorder with low platelets) and chronic hepatitis B virus infection. Forty-eight participants took the daily pill for 6 weeks, with some continuing for up to 22 weeks if they responded well. The main goal was to see if the drug could get platelet counts to a safer level to reduce bleeding risk.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HBV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.